Medical-device market access · Brazil
Brazil's 2026 regulatory reset
Run reliance, UDI, and clinical evidence as one playbook.
Regulatory snapshot
Reviewed 30 September 2026
Reliance · UDI · clinical evidence
General information, not legal advice
September 30, 2026
7
min read
By
Julio G. Martinez-Clark, CEO, bioaccess®
The short answer
In the last eighteen months, ANVISA has done more to reshape Brazil's medical device market-access rules than in the previous decade. The sponsors entering Brazil fastest in 2026 treat it as one evidence-to-market operating plan — not three disconnected workstreams.
$25B
Brazil's projected medical-device market by 2032, up from an estimated $15.28B in 2024 — an analyst estimate, not an official statistic.
In this analysis
Add this insight to your email
Copy a concise sponsor-ready paragraph based on the article.
In the last eighteen months, ANVISA has done more to reshape Brazil's medical device market-access rules than in the previous decade. There is now an optimized reliance pathway for high-risk devices, an operational unique device identification database, and a deepening reliance corridor with Mexico's COFEPRIS. Most U.S. startups still plan Brazil as three disconnected workstreams — clinical trial, registration, commercialization — each handed to a different vendor on a different timeline. That approach now costs real time and money.
The sponsors entering Brazil fastest in 2026 treat it as one evidence-to-market operating plan: generate the right clinical evidence, route it through the reliance pathway, build UDI into launch readiness, and line up public and private adoption from day one. Here is what changed, and what to do about it.
The prize is getting bigger
Brazil remains Latin America's largest medtech market by a wide margin. Fortune Business Insights estimates the Brazil medical devices market at USD 15.28 billion in 2024, growing to USD 25.00 billion by 2032 at a 6.4% compound annual rate, with in-vitro diagnostics as the leading segment.[[1]](#ref-1) These are analyst estimates, not official statistics, but the direction is consistent across forecasters: Brazil is a growth market, not a maintenance market. For a U.S. startup, Brazil is no longer a "later" market — it is the market that can anchor your entire Latin America strategy, especially now that Mexico formally recognizes ANVISA's evaluations.
1. Use reliance — correctly
ANVISA's Normative Instruction 290/2024, issued under RDC 741/2022, gives Class III and IV device registration petitions access to an "optimized analysis procedure" that leverages prior analyses by Equivalent Foreign Regulatory Authorities (EFRAs).[[2]](#ref-2) The recognized authorities are specific: Australia's TGA, Health Canada, the U.S. FDA (510(k) clearance, PMA, or De Novo), and Japan's MHLW.[[2]](#ref-2b)
Two details matter enormously, and both are frequently misunderstood. First, the European Union is not on the list — a CE mark alone does not qualify a device for this pathway. Second, this is optimized analysis, not recognition, waiver, or automatic approval. The device must have been approved by at least one EFRA, and the foreign documentation must cover a device essentially identical to the one submitted in Brazil: same indications and intended use, same manufacturers.[[2]](#ref-2c) ANVISA keeps the final decision and can still require Brazil-specific data.[[3]](#ref-3)
The practical implications for a startup:
- Sequence your clearances. If Brazil is on the roadmap, get the FDA or Health Canada clearance positioned ahead of the Brazilian filing, and treat the foreign dossier as the asset it is — one that determines your Brazil timeline.
- Freeze early. Model names, indications, and manufacturing sites should be locked before the foreign clearance, not after. A late indication tweak for the U.S. launch can break the "essentially identical" test and push your Brazil petition back into ordinary analysis.
- Don't budget it as a rubber stamp. Sponsors that model reliance as a guaranteed shortcut are the ones surprised by Brazil-specific questions. Model it as a faster, more predictable lane — and keep contingency for ANVISA's own review.[[4]](#ref-4)
2. Turn Brazil into your Latin America springboard
In August 2025, ANVISA and Mexico's COFEPRIS signed a memorandum of understanding on regulatory reliance and information exchange, under which COFEPRIS recognized ANVISA as a Reference Regulatory Authority for expedited medical device registration and for recognition of ANVISA-issued GMP certificates.[[5]](#ref-5) For devices, the route is COFEPRIS's registration by equivalence under the guidelines published in the DOF on July 18, 2025, which give COFEPRIS a maximum of 30 business days to decide (art. 38).[[7]](#ref-7) A separate route for medicines only, published in the DOF on September 2, 2026, lets COFEPRIS build on ANVISA's prior assessment with no new technical review of aspects already evaluated by the Brazilian agency, and sets a 45-business-day maximum once complete documentation is submitted (art. 32); it took effect 30 business days after publication.[[12]](#ref-12)
This changes the math on Brazil-first strategies. A Brazil registration is no longer just access to one market — it is discounted access to Mexico, the region's second-largest device market. Plan the pair together: the same dossier logic that qualifies for ANVISA's optimized analysis can carry into COFEPRIS's abbreviated route. (Note that Mexico also runs a separate equivalence agreement for FDA- and Health Canada-authorized devices — a different route with different rules. Do not confuse the two.)[[8]](#ref-8)
3. Build UDI into launch readiness now
On February 13, 2026, ANVISA published Normative Instruction 426/2026, the operating rulebook for SIUD — Brazil's unique device identification database, required by RDC 591/2021.[[9]](#ref-9) The database is live, the grace period is over, and the obligations now sit squarely on registration holders:
- UDI data must be transmitted to SIUD before the device is placed on the Brazilian market, and it must match ANVISA-approved product information — equivalence is the holder's responsibility.[[9]](#ref-9b)
- Only the UDI-DI component is submitted; the UDI-PI stays inside the company's quality management system for traceability.[[9]](#ref-9c)
- The registration holder is responsible for transmission but may authorize a third party to do it.[[9]](#ref-9d)
- Corrections are permitted within 60 calendar days after publication; changes that require a new UDI-DI must be processed within 30 days; discontinued or cancelled devices must be inactivated within 30 days.[[9]](#ref-9e)
- Mandatory deadlines phase in by risk class under RDC 591/2021, with voluntary early submission allowed.[[10]](#ref-10)
For foreign startups, this makes your Brazilian registration holder selection more consequential: your BRH now needs SIUD transmission capability, not just filing capacity. Assign the UDI workstream an owner and a calendar now — device model by device model — and keep your ANVISA-approved data and your SIUD data synchronized. The companies scrambling in 2027 will be the ones that treated UDI as an IT afterthought.[[11]](#ref-11)
4. Generate evidence where you plan to sell
None of the above replaces clinical evidence — in fact, reliance raises its value. When ANVISA leans on a foreign authority's analysis, Brazil-specific clinical data and key-opinion-leader engagement become the differentiators that de-risk both the registro and downstream adoption in SUS and the private system. Brazil's clinical-trial framework also modernized under Law 14.874/24, with ANVISA now operating under firm review clocks for device studies.
The practical move: if Brazil is a launch market, generate evidence there. In-country data feeds the registration dossier, builds the KOL base that drives hospital adoption, and creates the registry infrastructure that payers increasingly expect. Sponsors that run their early-feasibility or first-in-human work in Brazil arrive at registration with data, relationships, and a market story — not just a dossier. Service firms that run cross-border regulatory and clinical programs, such as ElendiLabs, increasingly anchor that evidence strategy in Brazil for exactly this reason.
What to do this quarter
- Map your device against the IN 290/2024 EFRA list. If you hold FDA or Health Canada clearance, verify the "essentially identical" conditions now — indications, models, manufacturers.
- Freeze indications, model nomenclature, and manufacturing sites before your next foreign clearance if Brazil is on the roadmap.
- Pair Brazil and Mexico in one plan. Price Mexico into your Latin America timeline: up to 30 business days for a COFEPRIS device registration by equivalence (45 business days applies only to medicines on the ANVISA-based route), and keep it distinct from Mexico's separate FDA/Health Canada equivalence route.
- Confirm your Brazilian registration holder can transmit to SIUD. Assign UDI ownership, and calendar the risk-class deadlines from RDC 591/2021.
- Decide whether Brazil generates your launch evidence — and budget the trial accordingly. Evidence built in-market is the one asset that strengthens the registration, the KOL network, and payer conversations simultaneously.
The bottom line
Brazil's message in 2026 is consistent: the regulator is meeting sponsors halfway — faster analysis through reliance, a functioning UDI system, and regional recognition of its evaluations. But it rewards sponsors who plan the whole journey at once. One evidence-to-market plan, built now, beats three workstreams bolted together later.
Julio G. Martinez-Clark is CEO of bioaccess, a first-in-human CRO running early-stage clinical trials across Latin America.
Frequently asked questions
Does ANVISA's IN 290/2024 reliance pathway accept a CE mark?
No. The recognized Equivalent Foreign Regulatory Authorities are Australia's TGA, Health Canada, the U.S. FDA (510(k) clearance, PMA, or De Novo), and Japan's MHLW. The European Union is not on the list — a CE mark alone does not qualify a device for this pathway.
Is IN 290/2024 an automatic approval?
No. It is an optimized analysis procedure, not recognition, waiver, or automatic approval. The device must be essentially identical to the foreign-cleared version — same indications and intended use, same manufacturers — and ANVISA keeps the final decision and can still require Brazil-specific data.
What does a Brazil registration unlock in Mexico?
It depends on the product. For medical devices, COFEPRIS registers by equivalence with reference regulatory authorities under the guidelines published in the DOF on July 18, 2025, with a 30-business-day maximum for its decision (art. 38). For medicines only, separate guidelines published in the DOF on September 2, 2026 let COFEPRIS build on ANVISA's prior assessment with no new technical review of aspects ANVISA already evaluated, with a 45-business-day maximum once complete documentation is submitted (art. 32); they took effect 30 business days after publication.
What are the SIUD obligations for registration holders?
Under IN 426/2026, UDI data must be transmitted to SIUD before the device is placed on the Brazilian market and must match ANVISA-approved product information. The registration holder is responsible for transmission but may authorize a third party; corrections are permitted within 60 calendar days of publication, and a change that requires a new UDI-DI must be processed within 30 calendar days of its DOU publication (IN 426/2026, art. 7).
Regulatory sources
- Fortune Business Insights, Brazil Medical Devices Market (2025–2032) — analyst estimate, not an official statistic.
- ANVISA, Normative Instruction No. 290/2024 (English, official PDF) — optimized analysis procedure for Class III/IV registro petitions.
- Demarest, "ANVISA approves regulations on using analyses by Equivalent Foreign Regulatory Authorities (reliance)".
- RegDesk, "Enhancing Efficiency: ANVISA's IN 290/2024 Streamlines Regulatory Processes".
- ANVISA, "Anvisa fortalece cooperação regulatória com a Cofepris" (Aug 28, 2025) — ANVISA–COFEPRIS MoU.
- GaBI, "Brazil and Mexico forge alliance to streamline medical approvals and boost production".
- DOF, July 18, 2025: Lineamientos generales para la aplicación de la vía regulatoria abreviada — registration by equivalence with reference regulatory authorities; art. 38: 30 business days for medical devices.
- MassDevice, "Mexico enacts equivalence agreement for medical devices" — Mexico's separate FDA/Health Canada equivalence route.
- ANVISA, Normative Instruction No. 426/2026 (English, via CBDL) — SIUD operating rulebook.
- BRISA, ANVISA Normative Instruction 426/2026 (English PDF).
- Pure Global, "ANVISA Normative Instruction 426/2026 on UDI Database".
- DOF, September 2, 2026: vía regulatoria abreviada for medicines based on ANVISA — medicines only; art. 32: 45 business days; in force 30 business days after publication.
This regulatory snapshot reflects the instruments reviewed as of 30 September 2026. Market figures are analyst estimates, not official statistics. Regulators revise lists, annexes and filing practice; verify the current official text before making a filing decision. General information only, not legal advice.
Plan the whole journey at once.
bioaccess helps medical-device teams build first-in-human and market-entry programs across Latin America around the evidence they already have — and the approvals they still need.